NYKODE
Nykode Therapeutics is a clinical-stage biopharmaceutical platform that develops technology for novel vaccines and immunotherapy against HPV-induced malignancies.
NYKODE
Social Links:
Industry:
Biotechnology Clinical Trials Pharmaceutical
Founded:
2007-01-01
Address:
Oslo, Oslo, Norway
Country:
Norway
Website Url:
http://www.vaccibody.com
Total Employee:
11+
Status:
Active
Contact:
47 22 95 81 90
Email Addresses:
[email protected]
Total Funding:
31.73 M EUR
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS Person Schema Gravatar Profiles WebEx
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Immutep
Immutep is a biopharmaceutical company developing immunotherapeutics in oncology.
NovaBay Pharmaceuticals
NovaBay Pharmaceuticals is a biopharmaceutical company developing products for the eye care market.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Current Employees Featured
Founder
Stock Details
Investors List
Norwegian Research Council
Norwegian Research Council investment in Venture Round - Nykode
Kreftforeningen
Kreftforeningen investment in Venture Round - Nykode
Kreftforeningen
Kreftforeningen investment in Venture Round - Nykode
Norwegian Research Council
Norwegian Research Council investment in Seed Round - Nykode
Norwegian Research Council
Norwegian Research Council investment in Grant - Nykode
Official Site Inspections
http://www.vaccibody.com
- Host name: hvaler.tornado-node.net
- IP address: 195.159.29.35
- Location: Norway
- Latitude: 59.9452
- Longitude: 10.7559
- Timezone: Europe/Oslo
More informations about "Nykode"
Home - Nykode
Nov 8, 2024 · The Nykode Therapeutics platform is built around the Vaccibody molecule. Inducing fast, strong and long-lasting immune responses, and demonstrating a positive safety profile, …See details»
Vaccibody becomes Nykode Therapeutics - Nykode
Company Announcement - vaccibody.com
Nykode Therapeutics, is a clinical-stage biopharmaceutical company, dedicated to the discovery and development of vaccines and novel immunotherapies for the treatment cancer and …See details»
Annual Report 2020 - vaccibody.com
The organization from 24 employees at the end of 2019 to 51 at the end of 2020. We expect to continue to significantly increase the Vaccibody organization in order to execute our ambitious …See details»
Nykode - Crunchbase Company Profile & Funding
Nykode Therapeutics is a clinical-stage biopharmaceutical platform that develops technology for novel vaccines and immunotherapy against HPV-induced malignancies. A therapeutic cancer …See details»
Company Announcement - nykode.com
Oslo, Norway, November 24, 2021 – Nykode Therapeutics (formerly Vaccibody*) (Euronext Growth (Oslo): VACC) refers to the announcement made on November 23, 2021 regarding the …See details»
Vaccibody becomes Nykode Therapeutics, teams up with …
Nov 23, 2021 · Vaccibody, a Norway-based pioneer in the neoantigen cancer vaccine space, has changed its name to Nykode Therapeutics, and has entered into a license and collaboration …See details»
In a Blockbuster Day, Vaccibody Gets New Name and a Multi …
Nov 24, 2021 · On November 23rd, Norway-based Vaccibody AS announced changing its name to Nykode Therapeutics. The new name meaning “new code” embraces the company’s …See details»
Vaccibody rebrands as Nykode, and unveils big Regeneron …
Nov 24, 2021 · Norwegian biotech Vaccibody has changed its name to Nykode Therapeutics, and celebrated its new identity with a sizeable deal with Regeneron to develop vaccines for cancer …See details»
Vaccibody Becomes Nykode Therapeutics - Business Wire
Nov 23, 2021 · Nykode Therapeutics, is a clinical-stage biopharmaceutical company, dedicated to the discovery and development of vaccines and novel immunotherapies for the treatment …See details»
Vaccibody rebrands to Nykode and bags $925m deal with …
Nov 24, 2021 · The lucrative new partnership comes just over a year after Nykode (then Vaccibody) penned a deal with Roche-owned Genentech for the joint development and …See details»
Vaccibody, now Nykode, celebrates new name with a Regeneron …
Nov 23, 2021 · Norwegian vaccine and immunotherapy biotech Vaccibody has changed its name to Nykode Therapeutics to “signify a new phase of growth and developmen t,” and it started …See details»
Technology platform - Nykode
Nykode Therapeutics' technology platform rethinks conventional drug design through its intelligent modular design and hyper-targeting, specifically tailored to each disease. The platform opens …See details»
COMPANY ANNOUNCEMENT - vaccibody.com
Vaccibody AS, is a clinical-stage biopharmaceutical company, dedicated to the discovery and development of vaccines and novel immunotherapies. The Company develops vaccines for …See details»
Genentech pays $200M for Vaccibody's phase 1 cancer vaccine
Oct 1, 2020 · Genentech has secured a global license to neoantigen cancer vaccines developed by Vaccibody. The Roche subsidiary is set to hand over $200 million in upfront and near-term …See details»
Using the Vaccibody platform to generation vaccines against …
Vaccibody™immunotherapy platform targets antigens to Antigen Presenting Cells (APCs) for a rapid, broad and controlled immune response Unique Vaccibody construct can be delivered by …See details»
Company overview - vaccibody.com
Vaccibody is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies. The company is a leader in the rapidly developing …See details»
Vaccibody reports promising preclinical data with a second
Discovery and development of novel immunotherapies. The Company develops vaccines for the treatment cancer and infectious diseases. Vaccibody’s vaccine technology specifically targets …See details»
Vaccibody gets a new name and loads up with nearly $1B in …
Nov 23, 2021 · Vaccibody who? A little over a year after securing a $700 million-plus deal with Roche for its neoantigen cancer vaccine, the Norwegian biotech has attracted yet another Big …See details»
DNA vaccine candidates to address emerging variants of concern
Vaccines for the treatment of cancer and infectious diseases. Vaccibody’s vaccine technology specifically targets antigens to Antigen Presenting Cells, which are essential for inducing rapid, …See details»